<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert syndrome</z:e> have an impaired function of the enzyme UGT1A1, responsible for the degradation of 4-OH-<z:chebi fb="1" ids="50114">estrogens</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>These elements are produced by the degradation of <z:chebi fb="1" ids="50114">estrogens</z:chebi> and are well-known carcinogens </plain></SENT>
<SENT sid="2" pm="."><plain>In theory, patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert syndrome</z:e> accumulate 4-OH-<z:chebi fb="1" ids="50114">estrogens</z:chebi> and, therefore, might have a higher risk for <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, especially when exposed to higher levels of <z:chebi fb="1" ids="50114">estrogens</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>If this theory is true, a new risk group for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> would be described, producing new insights in breast <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
</text></document>